FIELD: chemistry.
SUBSTANCE: novel compounds of formula or their pharmaceutically acceptable salts or stereoisomers have cathepsin K, L, S and B inhibitory properties. In the formula R1 and R2, taken together with the carbon atom with which they are bonded, form a C3-4cycloalkyl; R3 is C1-6alkyl which is substituted with one-four fluorine or chlorine atoms; R4 is a C1-6alkyl which is substituted with one-five halogen atoms; R5 is hydrogen; each D independently denotes phenyl; R6 is hydrogen or C1-6alkyl, which can be substituted with one-two hydroxyl groups or two-six halogen atoms; R7 is C1-6alkyl which can be substituted with two-five halogen atoms; n equals two. The invention also relates to a pharmaceutical composition and to use of said compounds to prepare a medicinal agent.
EFFECT: more effective use of the compounds.
8 cl, 12 ex
Title | Year | Author | Number |
---|---|---|---|
CATHEPSIN-CYSTEINE PROTEASE INHIBITORS | 2003 |
|
RU2312861C2 |
NOVEL CYCLOPENTANE DERIVATIVES | 2010 |
|
RU2572555C2 |
PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | 2010 |
|
RU2535479C2 |
NEW AZETIDINE DERIVATIVES | 2013 |
|
RU2629114C2 |
PYRAZOLE COMPOUND AND ITS PHARMACEUTICAL USE | 2012 |
|
RU2617678C2 |
BETA-SECRETASE INHIBITORS | 2016 |
|
RU2712272C2 |
CATHEPSIN CYSTEINE PROTEASE INHIBITORS | 2014 |
|
RU2692799C2 |
BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOHUANIDINE COMPOUNDS, USEFUL FOR THE TREATMENT OF PAIN | 2013 |
|
RU2664541C2 |
OXAZINMONOACYLGLYCERIN LIPASE (MAGL) INHIBITORS | 2019 |
|
RU2794334C2 |
PERMEABLE GLYCOSIDASE INHIBITORS AND USE THEREOF | 2013 |
|
RU2707292C2 |
Authors
Dates
2010-09-20—Published
2005-11-18—Filed